GLP-1 Medicines After a Thyroidectomy: It Depends on Why It Was Removed

It depends on why your thyroid was removed.

If you or any member of your family has ever had medullary thyroid carcinoma (MTC), a less common type of thyroid cancer, all seven FDA labels covered here say not to use the medicine. The same applies if you have multiple endocrine neoplasia syndrome type 2 (MEN 2), an inherited condition linked to MTC, and none of the labels makes an exception once the thyroid is gone.^{1, 2, 3, 4, 5, 6, 7, 8}

If it was removed for papillary or follicular cancer, a goiter, benign nodules or Graves' disease, those reasons are not on the labels' list.^{1, 2, 3, 4, 5, 6, 7} Make the decision with the endocrinologist or surgeon who has your pathology report and knows your family history.

If you take thyroid hormone such as levothyroxine, ask how your levels will be checked once you start. In a study reported on two of the labels, semaglutide tablets raised exposure to a single levothyroxine dose by 33%.^{3, 5}

What the labels say for each reason a thyroid is removed

Seven FDA labels cover these drugs: Zepbound and Mounjaro (tirzepatide); Wegovy, Ozempic and the Rybelsus and Ozempic tablets (semaglutide); Foundayo (orforglipron); and Saxenda (liraglutide). If more than one reason below fits you, the strictest one applies. Each row of the table summarizes the section it links to, where the sources are.

Medullary thyroid carcinoma, MEN 2 or a relative with MTC

If you have had MTC, the labels say not to use these drugs, even if surgery appears to have cured it.^{1, 2, 3, 4, 5, 6, 7} MTC makes up 1% to 2% of U.S. thyroid cancers. It starts in the thyroid's C cells and can return, sometimes many years after successful treatment, which is why its follow-up includes blood tests for calcitonin and CEA, two markers that MTC typically raises.⁸

MEN 2 rules these drugs out too, with or without a thyroid.^{1, 2, 3, 4, 5, 6, 7} When testing after a relative's MTC finds an inherited change in the RET gene, the thyroid can be removed before MTC has a chance to develop.⁸ If that is why yours came out, the family-history part of the rule applies to you, and so does the MEN 2 part if your doctors have diagnosed MEN 2. Surgery changes neither.

A relative's MTC counts whatever the reason for your own surgery, so find out, if you can, which type of thyroid cancer a relative had.^{1, 2, 3, 4, 5, 6, 7} If that is you, these medicines are not an option; ask your endocrinologist what else could help with your weight.

Papillary or follicular thyroid cancer

These common types, together called differentiated thyroid cancer, are not on the labels' list.^{1, 2, 3, 4, 5, 6, 7, 9} A study first published online in February 2026, which its authors describe as the first of its kind, followed people with this cancer at Memorial Sloan Kettering Cancer Center in New York. It compared 536 who took a GLP-1 drug, including semaglutide or tirzepatide, with 536 matched patients who never did.¹⁰

Over a median of 69 months, use was not significantly linked to the cancer coming back or growing. The study's two analyses gave hazard ratios of 0.87 and 0.75, where 1 would mean no difference, and neither result was statistically significant.¹⁰

The authors conclude that eligible patients should not be denied these drugs when there is a medical reason for them. They also note the limits: the study looked back at one cancer center's records, median use was 16 months, and factors they could not measure may have shaped the result.¹⁰

The British Thyroid Foundation, a UK patient charity, says people with these cancers should weigh the risks and benefits with their doctor and are often able to take these drugs once cancer treatment is complete.¹¹ Your usual cancer follow-up, such as neck ultrasounds and blood tests for thyroglobulin (a protein made by thyroid tissue and by these cancers), continues.⁹

Goiter, benign nodules or Graves' disease

None of these is on the labels' list.^{1, 2, 3, 4, 5, 6, 7} When surgery is done for Graves' disease or a large goiter, the whole thyroid is usually removed, which means thyroid hormone for life.¹² The British Thyroid Foundation sees no specific reason people with benign thyroid conditions should avoid these drugs, though it says waiting until your thyroid hormone levels are normal may be wise.¹¹

Only part of the thyroid removed (lobectomy or hemithyroidectomy)

After a lobectomy (also called a hemithyroidectomy), which removes one side, the answer still turns on why it was done, and you may not need thyroid hormone at all.^{12, 13} The remaining lobe is still thyroid tissue, and the labels say a nodule found on an exam or neck scan should be checked further.^{1, 2, 3, 4, 5, 6, 7}

Before anyone prescribes a GLP-1 medicine

Whoever the prescriber is, have these ready:

• Why your thyroid was removed. If you no longer have the pathology report or the operative note, ask the surgeon's office or the hospital's records department for copies.
• Any relative who has had MTC, or a thyroid cancer of unknown type, and any RET gene test result or MEN 2 diagnosis.
• Your levothyroxine dose and your latest TSH result.
• Any planned surgery or procedure, and any plan to become pregnant.

Why removing the thyroid does not lift the warning

The labels' boxed warning comes from animal studies. In rats or mice, semaglutide, tirzepatide and liraglutide caused tumors of the thyroid's C cells.^{1, 2, 3, 4, 5, 7} For all seven drugs, it is not known whether the drug causes thyroid tumors, including MTC, in people.^{1, 2, 3, 4, 5, 6, 7}

Foundayo's label carries a boxed warning with the same title, Risk of Thyroid C-Cell Tumors, and the same contraindication for MTC and MEN 2. Its drug, orforglipron, "is not pharmacologically active in rats or mice," so rodent studies could not show whether it causes these tumors. It is active at the human GLP-1 receptor, though, and the label says the human relevance of the C-cell tumors seen in rodents with other GLP-1 drugs has not been determined.⁶

C cells sit inside the thyroid, so removing it can look like removing the concern. None of the labels makes that exception.^{1, 2, 3, 4, 5, 6, 7, 8}

Levothyroxine and other pills once you start

If you take thyroid hormone, the dose is checked with a blood test for TSH (thyroid-stimulating hormone), which shows whether it is right.⁹ These drugs raise two questions for anyone on levothyroxine. They slow stomach emptying, which may change how much of each pill your body absorbs, and the weight you lose can change the dose you need.^{1, 14}

The 33% figure comes from a study by the tablets' maker, Novo Nordisk. It gave 45 healthy adults a single 600-microgram dose of levothyroxine, so it cannot show what happens with daily doses in someone without a thyroid. Its authors conclude that monitoring thyroid levels should be considered in people who take both.¹⁸

Four labels name pills with a narrow therapeutic index, meaning a small margin between too little and too much. Zepbound's and Mounjaro's say to monitor people who take them, and Wegovy's and the Rybelsus and Ozempic tablets' say to consider extra clinical or laboratory monitoring.^{1, 2, 3, 5} Levothyroxine is one of these pills: Synthroid's label says it has a narrow therapeutic index and that too much or too little may affect the heart, bones and other body systems.¹⁹

Weight loss matters too. The American Thyroid Association notes that the levothyroxine dose is often related to body weight. In a study it summarized, more than half of 1,030 people with hypothyroidism needed a dose change after weight-loss surgery, most often a lower one.¹⁴

Two case reports, published in 2024 and 2026, describe women who were stable on levothyroxine for years after a total thyroidectomy. After they started semaglutide injections or tirzepatide, their TSH fell below normal, a sign of too much thyroid hormone, and both needed a lower dose.^{20, 21} The second woman had dizziness, a racing heartbeat, weakness and confusion, and she needed urgent dose reduction and supportive care; she had also had weight-loss surgery. Single cases cannot show how often this happens.²¹

Too much levothyroxine can cause an irregular or racing heartbeat, nervousness, trouble sleeping, tremors and muscle weakness, and it may bring on chest pain (angina) in some people. The label tells patients to notify their healthcare provider about a rapid or irregular heartbeat, chest pain, shortness of breath, nervousness, sleeplessness or tremors, among other symptoms.¹⁹ Wegovy's and Saxenda's labels also tell patients to report palpitations or a racing heartbeat at rest, so a new racing heartbeat can have more than one cause.^{3, 7}

If you notice any of these after you start, contact the clinician who manages your levothyroxine promptly instead of waiting for your next scheduled check. For chest pain, fainting or trouble breathing, get emergency care.

None of this means changing your dose on your own. Ask the clinician who manages your levothyroxine when to check your TSH after you start. For reference, the levothyroxine label calls for a TSH check 6 to 8 weeks after a dose change in adults with primary hypothyroidism, and a review of symptoms and blood tests every 6 to 12 months on a stable dose and whenever your health changes.¹⁹ The British Thyroid Foundation says you may need a TSH check about 2 to 3 months after substantial weight loss.¹¹

If your cancer team keeps your TSH in a set range, tell them before you start.⁹ Semaglutide tablets and levothyroxine are both taken on an empty stomach, so ask your prescriber or pharmacist how to fit them together.^{3, 5, 19} Some people need calcium after thyroid surgery, and the levothyroxine label says calcium and iron supplements and antacids can decrease its absorption, so ask how to space them; our page on vitamins and supplements with tirzepatide covers the question.^{12, 19} The same question applies to the calcium and iron in PlexusDx's supplement packs.

The same slower stomach can make birth-control pills less reliable. Zepbound's and Mounjaro's labels advise switching to a birth-control method you don't swallow, or adding a barrier method alongside the pill, for the first 4 weeks on the drug and for 4 weeks after each step up in dose. For Foundayo, the label sets the same window at 30 days.^{1, 2, 6}

Studies in people: what they found and who they left out

None of the studies below was designed for people whose thyroid is already gone. Apart from the Memorial Sloan Kettering recurrence study above and the two case reports under levothyroxine, a PubMed search on October 3, 2026 found no study that followed people who started these drugs after thyroid surgery.²² The American Thyroid Association's list of guidelines and statements showed nothing on GLP-1 drugs that day.²³

Most research asks whether these drugs cause new thyroid cancers in people who still have a thyroid, often adults with type 2 diabetes. The findings differ, and each study has limits.

• France, 2023. Among adults with type 2 diabetes, 1 to 3 years of GLP-1 use was linked with a 58% higher risk of any thyroid cancer and a 78% higher risk of MTC.²⁴ The study compared users with non-users. Scandinavian researchers note that this can leave other differences between the groups, and that a risk appearing early and not growing with longer use could reflect more testing.²⁵
• Denmark, Norway and Sweden, 2024. Thyroid cancer rates were similar in 145,410 people starting a GLP-1 drug and 291,667 starting another diabetes drug, followed for 3.9 years on average (hazard ratio 0.93). The MTC estimate was too imprecise to read. The study excluded anyone who had ever had thyroid cancer, most users took liraglutide, and semaglutide users were followed for about a year.²⁵
• Canada, Denmark, Norway, South Korea, Sweden and Taiwan, 2025. Six health databases showed no rise in thyroid cancer among 98,147 GLP-1 users compared with 2,488,303 users of another diabetes drug (hazard ratio 0.81). Follow-up was short (median 1.8 to 3.0 years), cancer types could not be separated, and the authors say a longer-term risk cannot be ruled out.²⁶
• United States, 2025. Among 351,913 adults with type 2 diabetes, starting a GLP-1 drug was not significantly linked to more thyroid cancer overall than starting one of three other diabetes drug classes (hazard ratio 1.24, 95% confidence interval 0.88 to 1.76). Risk was higher in the first year (hazard ratio 1.85), which the authors say may reflect earlier detection. In an as-treated sensitivity analysis, which stops counting people once they stop the drug or add another, it was higher still (hazard ratio 2.07, 95% confidence interval 1.10 to 3.95). In all, 0.17% of the GLP-1 group was diagnosed.²⁷
• Pooled trials, 2024. Across 64 trials lasting at least a year, thyroid cancer was more common with GLP-1 drugs (odds ratio 1.52, where 1 would again mean no difference), but only by about 1 case for every 1,349 people treated for 5 years. A single case going the other way would have erased the statistical significance, and papillary and medullary cancer were not significantly higher on their own.²⁸
• Pooled trials, December 2025. Across 48 placebo-controlled trials with 94,245 people, including semaglutide and tirzepatide trials, reviewers judged that these drugs probably have little or no effect on thyroid cancer risk. Their estimate ran from 1 fewer to 9 more cases per 10,000 people treated, and the trials were short and not designed to study cancer.²⁹
• Tirzepatide trials, 2025. Thirteen trials with 13,761 people, lasting 26 to 72 weeks, showed no rise in any type of cancer. Calcitonin, a C-cell blood marker, did rise more on the two highest doses than on placebo.³⁰
• Reports after approval. Five of the labels note MTC cases reported in people taking liraglutide and say those reports can neither establish nor rule out a causal link.^{3, 4, 5, 6, 7}

In October 2023, Europe's medicines regulator concluded that the evidence, including the French study, did not support a causal link, and it left its product information unchanged.³¹ That review did not cover tirzepatide or orforglipron, and the U.S. labels keep the boxed warning.^{1, 2, 3, 4, 5, 6, 7, 31}

Calcitonin tests and neck ultrasounds

The labels do not call for routine calcitonin blood tests or thyroid ultrasounds. They say such checks are of uncertain value for catching MTC early in people on these drugs and can lead to unnecessary procedures. A high calcitonin result, or a nodule found on an exam or scan, should be checked further.^{1, 2, 3, 4, 5, 6, 7} After thyroid cancer, keep the follow-up schedule your cancer team set.⁹

Beyond the thyroid: other risks on the labels

Apart from MTC and MEN 2, the only other group all seven labels rule out is anyone who has had a serious allergic reaction to the drug or anything in it. All seven also warn about pancreatitis, gallbladder disease, kidney injury from fluid loss, severe stomach and bowel reactions, serious allergic reactions, low blood sugar and food or liquid entering the lungs during anesthesia.^{1, 2, 3, 4, 5, 6, 7} Each drug's Medication Guide, the patient leaflet that comes with it, lists more. Go through them with your prescriber before you start, but a sign marked "right away" below does not wait for that conversation.

• Pancreatitis, including severe cases that have been fatal. Severe stomach pain that doesn't ease, sometimes spreading to your back: stop taking the drug and call your provider right away.¹
• Gallbladder disease, which happens more often on these drugs. Pain in the upper belly, a fever, skin or eyes turning yellow, or clay-colored stools: tell your provider right away.¹
• Kidney damage after losing fluids, which has sometimes required dialysis. If nausea, vomiting or diarrhea won't let up, keep drinking fluids and tell your provider right away.¹
• Serious allergic reactions. Swelling of your face, lips, tongue or throat; problems breathing or swallowing; fainting or feeling dizzy; a racing heartbeat; or a severe rash or itching: stop using it and seek medical help right away.¹
• Low blood sugar, most often when these drugs are taken alongside insulin or a sulfonylurea, a kind of diabetes pill. Cases in adults without type 2 diabetes appear on the Zepbound, Foundayo and Wegovy labels, and Saxenda's label reports cases in children aged 12 or over who do not have type 2 diabetes. Ask your prescriber how to spot and treat it; signs include shakiness, sweating, dizziness, confusion and a fast heartbeat.^{1, 3, 6, 7}
• Food or liquid getting into the lungs under anesthesia or deep sedation, a rare problem. Before any planned procedure, including more neck surgery, let every doctor and dentist know you take one of these drugs.¹
• Severe stomach and bowel side effects. If stomach problems turn severe or won't settle, call your provider. The labels do not recommend these drugs for people with severe gastroparesis, meaning a stomach that empties very slowly.^{1, 2, 3, 4, 5, 6, 7}
• Eye damage from diabetes (diabetic retinopathy) can get worse in people with type 2 diabetes; every label except Saxenda's carries this warning. Tell your provider about any change in your vision.^{1, 2, 3, 4, 5, 6}
• A thyroid tumor can show up as a new lump or swelling in the neck, a hoarse voice, difficulty swallowing or shortness of breath. After neck surgery these can have other causes, so report anything new rather than guessing.¹

If you could become pregnant, tell your prescriber before you start, and promptly if you become pregnant while taking one; the labels differ on what comes next. All seven warn that the drug may harm an unborn baby (for Mounjaro, Ozempic and the Rybelsus and Ozempic tablets, based on animal studies). Four (Zepbound, Wegovy, Foundayo and Saxenda) tell you to stop it once a pregnancy is recognized; Wegovy's instruction covers its weight and heart uses. Wegovy, Ozempic and the Rybelsus and Ozempic tablets need to be stopped at least 2 months before you plan to conceive, and Foundayo's label advises effective birth control while you take it.^{1, 2, 3, 4, 5, 6, 7}

The labels for Mounjaro, Ozempic and the Rybelsus and Ozempic tablets say these drugs "should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus," so if you become pregnant while taking one of them, call your prescriber rather than stopping on your own. Breastfeeding is not recommended with Wegovy tablets, the Rybelsus and Ozempic tablets or Foundayo.^{2, 3, 4, 5, 6}

Your other medicines: four labels (Zepbound, Wegovy, Foundayo and Saxenda) warn against using the drug with another GLP-1 medicine, and a compounded semaglutide or tirzepatide product would be one.^{1, 3, 6, 7} Foundayo's label also says to avoid medicines that strongly speed up the liver enzyme CYP3A4 and some that strongly slow it (ritonavir is one), lowers Foundayo's top dose with other strong CYP3A4 slowers, caps the dose of the cholesterol drug simvastatin taken with it, and does not recommend it in severe liver impairment.⁶

If you take too much, the Medication Guides say to call your provider, call Poison Help (1-800-222-1222) or go to the nearest hospital emergency room right away.^{1, 2, 3, 4, 5, 6, 7} Compounded semaglutide and tirzepatide have no FDA label or Medication Guide of their own, so go through this list with your prescriber for them too.

If you gained weight after surgery

Once hypothyroidism is treated and thyroid levels are normal, the American Thyroid Association says, the ability to gain or lose weight is the same as in people without thyroid problems.³² The drug labels' criteria, including the MTC and MEN 2 rule above, apply to you as to anyone else.

Used with a reduced-calorie diet and more physical activity, Zepbound, Wegovy, Foundayo and Saxenda carry FDA approval for long-term weight reduction for adults living with obesity, and for adults with overweight who also have at least one weight-related health condition; Wegovy injection and Saxenda also have uses for some children 12 and older.^{1, 3, 6, 7} In Zepbound's main trial, obesity meant a BMI of at least 30, and overweight a BMI from 27 to just under 30 with a weight-related condition.¹ Mounjaro, Ozempic and the Rybelsus and Ozempic tablets are approved only for uses in type 2 diabetes, such as improving blood sugar alongside diet and exercise.^{2, 4, 5} Some labels list other uses as well, for example Zepbound's for moderate to severe obstructive sleep apnea in adults with obesity.¹

For an adult who fits none of the labeled uses, a GLP-1 would be an off-label use, one FDA has not approved. Because your thyroid history changes the risks, talk first with the doctor who manages it, before using any online seller; PlexusDx, which publishes this page, is one. If that is your situation, read our guide for people without obesity or overweight.

Extra thyroid hormone is not a shortcut. Synthroid's boxed warning says thyroid hormones should not be used for obesity or weight loss, and that larger doses may cause serious or even life-threatening toxicity. The American Thyroid Association adds that weight lost this way usually returns once the extra hormone stops.^{19, 32}

If you are weighing a PlexusDx program

If you have had MTC, anyone in your family has, or you have MEN 2, the labels say these drugs are not for you. Compounded semaglutide and tirzepatide have no label of their own, and this page's advice is the same for them: do not start one.

If you are thinking about a program from PlexusDx, which publishes this page, take the reason-by-reason rules and the label warnings above to the prescriber, as you would for any GLP-1 medicine. Only adults 18 and older can use PlexusDx's programs.

Lone Star Virtual Health, PlexusDx's provider team, supplies the clinicians who control the medical side, from your evaluation to whether you get a prescription and at what dose; PlexusDx does not practice medicine, and qualifying is not guaranteed. PlexusDx does not sell or ship brand-name medications. If you would prefer a brand-name, FDA-approved medication, your provider may write a prescription you can fill at the pharmacy of your choice.

Tell the clinician everything on the first-appointment checklist above. Lone Star's physicians judge all three PlexusDx GLP-1 plans the same way: the BMI minimum is 25, or 22 for people who have had a GLP-1 drug within two months; the starting minimum is lower than the approved labels' (30, or 27 for someone with a weight-related health problem), so starting treatment in that range would be off-label. The intake asks every patient about a personal history of thyroid cancer and a family history of thyroid cancer or MEN 2, but not which type of thyroid cancer, and not whether you have MEN 2 yourself; those answers go to the physician rather than ending the intake, so say plainly whether your cancer was medullary (MTC) and whether you have MEN 2. It also asks about pancreatitis, gallbladder disease and pregnancy, but not about diabetic retinopathy, sedation for a planned procedure, or a B12 or glycine allergy.

Under PlexusDx's Terms of Service, the plan price does not include outside lab tests, so it does not cover the TSH checks described above; keep the clinician who manages your thyroid in charge of them. PlexusDx is self-pay and does not bill health insurance. Its Terms also note that a compounded medicine's formula, including any added ingredient, can differ from one pharmacy or fill to the next. Either drug can be taken weekly by injection or daily as a tablet that disintegrates in the mouth (ODT); no tirzepatide tablet is FDA-approved, and FDA has not approved any compounded semaglutide tablet. Its injections always include vitamin B12 or glycine; in California the intake lets you choose, while elsewhere the dispensing pharmacy decides without checkout saying which, and your label, or a call to the pharmacy, will show it. Per Lone Star, the add-in has to be clinically justified for the individual patient. No full ingredient list is published for the tablets. The physician reviews any allergy you report; the intake's allergy checklist leaves out B12 and glycine, so name them if they apply.

Compounded drugs are not FDA-approved. FDA says it "does not review compounded drugs for safety, effectiveness or quality before they are marketed" and that they "should only be used in patients whose medical needs cannot be met by an FDA-approved drug."¹⁶ FDA's guidance for compounding pharmacies adds that a lower price does not count as a valid reason to copy an approved drug.³³

In FDA's assessment, many of the side effects reported with compounded semaglutide and tirzepatide appear consistent with those of the approved drugs, and the reports are probably incomplete, since federal law does not make state-licensed pharmacies other than outsourcing facilities send them in. FDA has also received reports of harm, some involving patients who were hospitalized, that may be related to dosing errors involving compounded semaglutide injections.¹⁶ None of the studies above tested a compounded product, and we found no published study of compounded semaglutide or tirzepatide taken with levothyroxine.¹⁷

If a compounded product is offered, ask the prescriber why it suits you better than an FDA-approved medicine, and before you pay, run the six pre-payment checks on our compounded tirzepatide provider page. The legal rules are covered on our page about choosing a compounded tirzepatide provider.

Sources

1. ZEPBOUND (tirzepatide) injection: prescribing information and Medication Guide (revised August 2026), Eli Lilly and Company, via DailyMed, National Library of Medicine, accessed October 3, 2026.
2. MOUNJARO (tirzepatide) injection: prescribing information and Medication Guide (DailyMed version published September 2, 2026), Eli Lilly and Company, via DailyMed, National Library of Medicine, accessed October 3, 2026.
3. WEGOVY (semaglutide) injection and tablets: prescribing information and Medication Guide (revised June 2026), Novo Nordisk, via DailyMed, National Library of Medicine, accessed October 4, 2026.
4. OZEMPIC (semaglutide) injection: prescribing information and Medication Guide (DailyMed version published June 10, 2026), Novo Nordisk, via DailyMed, National Library of Medicine, accessed October 4, 2026.
5. RYBELSUS and OZEMPIC (semaglutide) tablets: prescribing information (DailyMed version published August 19, 2026), Novo Nordisk, via DailyMed, National Library of Medicine, accessed October 3, 2026.
6. FOUNDAYO (orforglipron) tablets: prescribing information (DailyMed version published August 13, 2026), Eli Lilly and Company, via DailyMed, National Library of Medicine, accessed October 4, 2026.
7. SAXENDA (liraglutide) injection: prescribing information and Medication Guide (DailyMed version published June 15, 2026), Novo Nordisk, via DailyMed, National Library of Medicine, accessed October 4, 2026.
8. Medullary Thyroid Cancer, American Thyroid Association, accessed October 3, 2026.
9. Thyroid Cancer (Papillary and Follicular), American Thyroid Association, accessed October 3, 2026.
10. Exposure to GLP-1RA and Risk of Structural Progression in Differentiated Thyroid Cancer, Patrizio A, et al., The Journal of Clinical Endocrinology and Metabolism, published online February 15, 2026 (June 2026 issue), accessed October 4, 2026.
11. Can I use weight loss injections (known as 'GLP-1' medications) if I have a thyroid condition?, British Thyroid Foundation, updated May 27, 2026, accessed October 3, 2026.
12. Thyroid Surgery, American Thyroid Association, accessed October 3, 2026.
13. Thyroidectomy (Thyroid Surgery): What It Is & Recovery, Cleveland Clinic, accessed October 4, 2026.
14. Thyroid hormone treatment after weight loss surgery (Clinical Thyroidology for the Public, January 2025), American Thyroid Association, accessed October 3, 2026.
15. Human Drug Compounding, U.S. Food and Drug Administration, content current as of June 15, 2026, accessed October 3, 2026.
16. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, U.S. Food and Drug Administration, content current as of October 1, 2026, accessed October 3, 2026.
17. PubMed search: compounded semaglutide or tirzepatide and levothyroxine (no records on October 3, 2026), National Library of Medicine, accessed October 3, 2026.
18. Effect of oral semaglutide on the pharmacokinetics of thyroxine after dosing of levothyroxine and the influence of co-administered tablets on the pharmacokinetics of oral semaglutide in healthy subjects, Hauge C, et al., Expert Opinion on Drug Metabolism and Toxicology, 2021, accessed October 4, 2026.
19. SYNTHROID (levothyroxine sodium) tablets: prescribing information (DailyMed version published February 29, 2024), AbbVie, via DailyMed, National Library of Medicine, accessed October 4, 2026.
20. Suppressed thyroid stimulating hormone levels after initiation of a subcutaneous glucagon-like peptide-1 receptor agonist in a post-thyroidectomy patient managed with levothyroxine case report, Wilcox L, Van Dril E, Journal of the American Pharmacists Association, November-December 2024 issue, accessed October 4, 2026.
21. Thyroid Dysfunction Following Tirzepatide Use in a Post-thyroidectomy Patient on Stable Levothyroxine Therapy: A Case Study, Adams EW, et al., Cureus, April 2026, accessed October 4, 2026.
22. PubMed search: GLP-1 drugs and thyroidectomy (10 records on October 3, 2026), National Library of Medicine, accessed October 3, 2026.
23. ATA Guidelines & Statements, American Thyroid Association, accessed October 3, 2026.
24. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer, Bezin J, et al., Diabetes Care, 2023, accessed October 3, 2026.
25. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study, Pasternak B, et al., BMJ, 2024, accessed October 3, 2026.
26. Glucagon-Like Peptide 1 Receptor Agonists and Risk of Thyroid Cancer: An International Multisite Cohort Study, Baxter SM, et al., Thyroid, 2025, accessed October 3, 2026.
27. GLP-1RA Use and Thyroid Cancer Risk, Brito JP, et al., JAMA Otolaryngology, Head and Neck Surgery, 2025, accessed October 4, 2026.
28. Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials, Silverii GA, et al., Diabetes, Obesity and Metabolism, 2024, accessed October 3, 2026.
29. Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists: A Systematic Review and Meta-analysis, Ko A, et al., Annals of Internal Medicine, published online December 2025 (February 2026 issue), accessed October 4, 2026.
30. Tirzepatide and Cancer Risk in Individuals with and without Diabetes: A Systematic Review and Meta-Analysis, Endocrinology and Metabolism, 2025, accessed October 3, 2026.
31. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 23-26 October 2023, European Medicines Agency, accessed October 3, 2026.
32. Thyroid and Weight, American Thyroid Association, accessed October 3, 2026.
33. Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry, U.S. Food and Drug Administration, January 2018, accessed October 3, 2026.

How we made this page

The question here is narrow: does the reason for a thyroidectomy change whether GLP-1 medicines can be used? On October 3 and 4, 2026, AI tools pulled the seven drug labels named above and the Synthroid (levothyroxine) label from DailyMed. They read the studies above through PubMed and Europe PMC, the American Thyroid Association's patient pages and guideline list, the British Thyroid Foundation's guidance, the European Medicines Agency's 2023 review, FDA's compounding pages and guidance, and a hospital system's description of thyroid surgery. A PubMed search on October 3 looked for research on people who started these drugs after thyroid surgery and for any study of compounded products with levothyroxine.

AI helped because the answer is scattered. The rule sits in seven drug labels, the levothyroxine evidence in other labels, a drugmaker's study and two post-thyroidectomy case reports, and the cancer research in eight studies of different groups of people. The tools drafted the page from those sources and tied each statement to a quoted passage, and a script then checked every quoted passage against the saved copies of the sources.

Other AI reviewers then read the draft for medical accuracy, regulatory wording and clarity. These automated steps check wording against sources; they do not replace a clinician's judgment. Where the sources stop, for example for people without a thyroid or for compounded products, the page says so rather than filling the gap. PlexusDx ran no study of its own for this page.

PlexusDx's own terms on this page are stated by us from its published Terms of Service and company records as of October 19, 2026, without source numbers. The earlier PlexusDx post at this address gave lab targets, waiting periods, extra contraindications and genetic-test advice that these sources do not support; nothing from it was carried over.

PlexusDx sells compounded GLP-1 treatment and other products, including supplement packs and at-home blood tests, so we have a financial interest in this topic. Dr. Asad K. Niazi, MD, MPH, reviewed the medical content on October 17, 2026. He is co-founder and CEO of Lone Star Virtual Health, the company that provides PlexusDx's prescribing clinicians, so he has a business relationship with PlexusDx. Jay Hastings, PlexusDx's CEO, reviewed this version and approved it on October 19, 2026. Our standards for every page are set out in our editorial policy.